“The U.S. Food and Drug Administration on Tuesday gave the nod to the first of a new class of medications against dry eye disease. Xiidra (lifitegrast) eyedrops are a newly developed type of drug called LFA-1 agonists, the agency explained in a news release.”
“Xiidra’s safety and effectiveness was assessed in more than 1,000 adults in four separate clinical trials. Patients received either Xiidra eyedrops or a placebo eyedrop twice daily for three months. According to the FDA, people taking Xiidra gained more improvement in “both the signs and the symptoms of eye dryness” compared to those taking the placebo.Side effects included eye irritation, blurred vision and “an unusual taste sensation,” the FDA said. Xiidra is made by Shire US, of Lexington, Mass.”
Read the full article: FDA Approves First of New Drugs for Dry Eye
Recent Posts
- Protected: The American Health Council Appoints Dr. Ivory Gordon onto the Industry Board October 22, 2018
- Protected: The American Health Council appoints Mr. Peter Kiongo to the Occupational Therapy Board October 22, 2018
- Protected: The American Health Council appoints Dr. Nija Walker to the Industry Board October 22, 2018
- The American Health Council Welcomes Dr. Paolo Benito Andres to the Board of Occupational Therapy October 19, 2018
- The American Health Council Appoints Dr. Robert C. Hall, DPT, MS, BS to the Physical Therapy Board October 19, 2018
- The American Health Council Appoints Ms. Kodi Pride to Occupational Therapy Board October 18, 2018
